Forecasting PARP Inhibitor Resistance in Breast Cancer Patients

Video
Conference|American Association for Cancer Research Annual Meeting (AACR)

In this video, Dr. Elizabeth Swisher reviews the use of PARP inhibitors in breast cancer, and the importance of understanding how resistance to these agents develops.

In this video, Dr. Elizabeth Swisher reviews the use of PARP inhibitors in ovarian cancer, and the importance of understanding how resistance to these agents develops.

Related Videos
Pegulicianine-guided breast cancer surgery may allow practices to de-escalate subsequent radiotherapy, says Barbara Smith, MD, PhD.
Barbara Smith, MD, PhD, spoke about the potential use of pegulicianine-guided breast cancer surgery based on reports from the phase 3 INSITE trial.
Carey Anders, MD, an expert on breast cancer
Carey Anders, MD, an expert on breast cancer
Carey Anders, MD, an expert on breast cancer
Carey K. Anders, MD, an expert on breast cancer
A panel of 4 experts on breast cancer seated at a long table
A panel of 4 experts on breast cancer seated at a long table
Related Content
Roshni Rao, MD, FACS, discussed the use of neoadjuvant chemoimmunotherapy and its complications in the treatment of patients with triple-negative breast cancer.

Questions Remain Around Neoadjuvant Chemoimmunotherapy in TNBC

April 22nd 2024
Article

Roshni Rao, MD, FACS, discussed the use of neoadjuvant chemoimmunotherapy and its complications in the treatment of patients with triple-negative breast cancer.

Sarah Donahue, MPH, NP, speaks to the importance of communicating potential adverse effects associated with treatments such as CDK4/6 inhibitors to patients with breast cancer.

Managing CDK4/6 Inhibitor, ADC Toxicity in Metastatic Breast Cancer

January 15th 2024
Podcast

Sarah Donahue, MPH, NP, speaks to the importance of communicating potential adverse effects associated with treatments such as CDK4/6 inhibitors to patients with breast cancer.

69 The Importance of Tri-Modality Therapy for De Novo Stage IV Invasive Lobular Carcinoma (ILC) Presenting With Bone-Only Metastases

69 The Importance of Tri-Modality Therapy for De Novo Stage IV Invasive Lobular Carcinoma (ILC) Presenting With Bone-Only Metastases

April 21st 2024
Article
HER2CLIMB-02 Trial Shows ‘Interesting Data’ in HER2+ Breast Cancer

HER2CLIMB-02 Trial Shows ‘Interesting Data’ in HER2+ Breast Cancer

January 8th 2024
Podcast

Tucatinib plus trastuzumab emtansine shows a progression-free survival improvement in HER2-positive breast cancer in the phase 3 HER2CLIMB-02 trial, says Sara A. Hurvitz, MD, FACP.

The latest KEYNOTE-756 data highlight the surgical outcomes of patients with high-risk early-stage estrogen receptor–positive breast cancer.

Neoadjuvant/Adjuvant Pembrolizumab Regimens Lower RCB in ER+ Breast Cancer

April 19th 2024
Article

The latest KEYNOTE-756 data highlight the surgical outcomes of patients with high-risk early-stage estrogen receptor–positive breast cancer.

Clipping of Lymph Nodes May Aid Axillary Surgery in Breast Cancer

Clipping of Lymph Nodes May Aid Axillary Surgery in Breast Cancer

April 19th 2024
Article

In clinically node-positive breast cancer, clipping of lymph nodes may induce higher rates of sentinel lymph node surgery after neoadjuvant chemotherapy.